Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms
✍ Scribed by Michael Riedel; Ilja Spellmann; Martin Strassnig; Anette Douhet; Sandra Dehning; Markus Opgen-Rhein; Rosamaria Valdevit; Rolf R. Engel; Nikolaus Kleindienst; Norbert Müller; Hans-Jürgen Möller
- Publisher
- Springer-Verlag
- Year
- 2007
- Tongue
- English
- Weight
- 233 KB
- Volume
- 257
- Category
- Article
- ISSN
- 1433-8491
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Negative symptoms are considered the most debilitating and refractory aspect of schizophrenia, being associated with poor social, occupational and global outcomes. Conventional antipsychotics have limited efficacy against these symptoms and poor tolerability profiles. Atypical antipsych
## Abstract ## Objective To examine the effects of risperidone and olanzapine on cognitive functioning in elderly patients with schizophrenia or schizoaffective disorder. ## Method One hundred seventy‐six elderly inpatients and outpatients with schizophrenia or schizoaffective disorder were enro
## Objective: To investigate the efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia. ## Method: Thirty-nine patients fulfilling dsm-iv-tr diagnostic criteria for schizophrenia and had depressive symptoms were studied in a prospective 6-week open-label design
## Abstract A post hoc analysis of data from three placebo‐controlled, double‐blind, randomized trials was carried out to determine the efficacy of quetiapine in aggression and hostility in patients with schizophrenia. Quetiapine treatment induced statistically significantly greater improvements in
This analysis of data from the open-label extension (OLE) phases of three randomized clinical trials of quetiapine in patients with schizophrenia (n=415) was undertaken to investigate whether the initial improvements in anxiety and depressive symptoms were maintained during long-term treatment. The